Cocrystal Pharma Reports Favorable Results from Single-Ascending Dose Cohorts of Phase 1 Study with CDI-988, its Oral Pan-Viral Norovirus/Coronavirus Protease Inhibitor
Overview
Stock Information
Nasdaq:
COCPPrice
![Loading...](https://content.equisolve.net/_c6110a9ed88425b202863df0273bacd1/cocrystalpharma/files/images/ajax-loader.gif)
Change
![Loading...](https://content.equisolve.net/_c6110a9ed88425b202863df0273bacd1/cocrystalpharma/files/images/ajax-loader.gif)
Mkt Cap
![Loading...](https://content.equisolve.net/_c6110a9ed88425b202863df0273bacd1/cocrystalpharma/files/images/ajax-loader.gif)
Volume
![Loading...](https://content.equisolve.net/_c6110a9ed88425b202863df0273bacd1/cocrystalpharma/files/images/ajax-loader.gif)
52 week Low/High
![Loading...](https://content.equisolve.net/_c6110a9ed88425b202863df0273bacd1/cocrystalpharma/files/images/ajax-loader.gif)
Day Low/High
![Loading...](https://content.equisolve.net/_c6110a9ed88425b202863df0273bacd1/cocrystalpharma/files/images/ajax-loader.gif)